Jaguar health reports third quarter 2023 financial results

Net revenue increased 5% in q3 2023 versus q2 2023 top line results expected before thanksgiving for company's phase 3 ontarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea reminder: jaguar to host investor webcast tuesday, november 14th at 8:30 a.m. eastern regarding q3 2023 financials and company updates; click here to register for webcast san francisco, ca / accesswire / november 14, 2023 / jaguar health, inc. (nasdaq:jagx) ("jaguar" or the "company") today reported consolidated third-quarter 2023 financial results and provided company updates.
JAGX Ratings Summary
Quant
JAGX Quant Ranking
Sector
Industry
Quant Rating
Quant Score